Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19

View ORCID ProfileAtul Varadhachary, Dev Chatterjee, Javier Garza, R. Patrick Garr, Christopher Foley, Andrea Letkeman, John Dean, David Haug, Juliet Breeze, Robbyn Traylor, Andrew Malek, Rohan Nath, Leo Linbeck III
doi: https://doi.org/10.1101/2020.08.07.20170258
Atul Varadhachary
1BreviTest Technologies, LLC and Fannin Innovation Studio, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Atul Varadhachary
  • For correspondence: atul@fannininnovation.com dev@fannininnovation.com
Dev Chatterjee
1BreviTest Technologies, LLC and Fannin Innovation Studio, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: atul@fannininnovation.com dev@fannininnovation.com
Javier Garza
1BreviTest Technologies, LLC and Fannin Innovation Studio, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Patrick Garr
1BreviTest Technologies, LLC and Fannin Innovation Studio, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Foley
1BreviTest Technologies, LLC and Fannin Innovation Studio, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Letkeman
1BreviTest Technologies, LLC and Fannin Innovation Studio, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Dean
1BreviTest Technologies, LLC and Fannin Innovation Studio, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Haug
2Arctas Capital Group, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juliet Breeze
3Next Level Urgent Care, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robbyn Traylor
3Next Level Urgent Care, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Malek
4Alchemy Industrial, LLC, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rohan Nath
5APC Health, Pearland, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo Linbeck III
1BreviTest Technologies, LLC and Fannin Innovation Studio, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Mucosal immunity, including secretory IgA (sIgA), plays an important role in early defenses against respiratory pathogens. Salivary testing, the most convenient way to measure sIgA, has been used to characterize mucosal immune responses to many viral infections including SARS, MERS, influenza, HIV, and RSV. However, its role has not yet been characterized in the COVID-19 pandemic. Here, we report development and validation of a rapid immunoassay for measuring salivary IgA against the SARS-CoV-2 virus, and report quantitative results in both pre-COVID-19 and muco-converted subjects.

Methods We developed and refined a specific test for salivary IgA against SARS-CoV-2 on the Brevitest platform, a rapid immunoassay system designed for point-of-care use. A qualitative test was validated as per FDA guidelines with saliva obtained from subjects prior to the emergence of COVID-19, and from PCR-confirmed COVID-19 patients. We also generated a quantitative measure of anti-SARS-CoV-2 salivary IgA. Time taken for saliva self-collection was measured and its ease-of-use assessed.

Results We successfully validated a qualitative salivary assay for SARS-CoV-2 IgA antibodies, with positive and negative predictive values of 92% and 97%, respectively, and no observable cross-reactivity with any of seven potential confounders. Pre-COVID-19 saliva samples showed an 8-fold range of IgA concentrations, suggesting a broad continuum of natural antibody resistance against the novel virus, though at levels lower than that observed in COVID-19 PCR-confirmed subjects. Samples from muco-positive subjects also shown a ~9-fold variation in salivary IgA levels, with elevated salivary IgA observed beyond three months after onset of symptoms. We observed a correlation (r=0.4405) between salivary IgA levels and COVID-19 disease severity. In anecdotal observations, we observed individuals who exhibited antibodies early in the course of their disease, contemporaneously with a positive PCR test, as well as individuals who muco-converted despite no known direct exposure to a COVID-19 patient, no symptoms, and negative molecular and/or serum antibody tests. Salivary collection took 5-10 minutes, and was reported as being easy (mean of 1.1 on a scale of 1 to 10).

Implications Mucosal immunity, including secretory IgA, plays an important role in host defense against respiratory pathogens, and our early data suggest it may do so in COVID-19. Salivary IgA, an accessible marker of mucosal immunity, may be a useful indicator of several key parameters including individual and community immune response, disease severity, clinical risk, and herd immunity. The non-invasive nature and ease of saliva collection facilitates its potential use as a biomarker for ongoing patient assessment and management, as well as a community surveillance tool. By measuring mucosal immune responses directly and systemic immune responses indirectly, salivary IgA could be useful in developing and deploying a vaccine(s) against COVID-19. Quantitative IgA assessment could also potentially serve as a tool to segment the population into different risk categories and inform individual and collective decisions relating to appropriate activities and vaccine prioritization/delivery. These data reinforce the importance of further investigation into the role of mucosal immunity and IgA in host responses against COVID-19.

Competing Interest Statement

AV, DC, JG, PG, AL, CF, LL are employees of BreviTest Technologies LLC., and Fannin Innovation Studio. JD is an intern at BreviTest Technologies, LLC.

Clinical Trial

Clinical trial protocol was used for sample collection. No subjects were treated.

Funding Statement

Development of the Brevitest platform was supported by the National Institute on Drug Abuse (NIDA) and the National Institute on Minority Health and Health Disparities (NIMHD) at the National Institutes of Health (NIH), Grant Numbers: 1 R43 DA041966-01; 1 R43 MD013409-01A1; 1 R43 DA043325-01, 2 R44 DA043325-02, 5 R44 DA043325-03; 3 R43 DA041966-01S1, the Vijay and Marie Goradia Foundation, and Fannin Innovation Studio.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The protocol and informed consent form for collection of saliva samples for this Minimal Risk Study received expedited approval by IntegReview IRB, Austin, TX.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Individual subject-level data included in the manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted August 11, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19
Atul Varadhachary, Dev Chatterjee, Javier Garza, R. Patrick Garr, Christopher Foley, Andrea Letkeman, John Dean, David Haug, Juliet Breeze, Robbyn Traylor, Andrew Malek, Rohan Nath, Leo Linbeck III
medRxiv 2020.08.07.20170258; doi: https://doi.org/10.1101/2020.08.07.20170258
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19
Atul Varadhachary, Dev Chatterjee, Javier Garza, R. Patrick Garr, Christopher Foley, Andrea Letkeman, John Dean, David Haug, Juliet Breeze, Robbyn Traylor, Andrew Malek, Rohan Nath, Leo Linbeck III
medRxiv 2020.08.07.20170258; doi: https://doi.org/10.1101/2020.08.07.20170258

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1240)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10023)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2453)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1643)
  • Health Policy (753)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11864)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2281)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (313)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4834)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)